Uncategorized
VIDEO: Bimatoprost SR implant shows sustained IOP lowering after three treatments
In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, E. Randy Craven, MD, discusses phase 3 data that showed a sustained IOP-lowering impact after three treatments with Durysta (bimatoprost implant, Allergan), regardless of the number of glaucoma medications patients were on before the treatment.